Quantifying cost savings from outpatient parenteral antimicrobial therapy programme: a systematic review and meta-analysis
JAC-Antimicrobial Resistance · 04.03.2025 · 7 (2)
DOI: 10.1093/jacamr/dlaf049 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 08.04.2025. Verfasst von Solomon Ahmed Mohammed und 9 weiteren Autor:innen. Beteiligte Einrichtung: UQ Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The outpatient parenteral antimicrobial therapy (OPAT) programme was introduced to reduce costs and enhance the quality of life for patients requiring prolonged treatment with parenteral antimicrobials. However, given the escalating inflation, the extent of current cost savings achieved through OPAT programmes remains unclear. This systematic review and meta-analysis employ a cost-minimization analysis to quantify the cost savings from OPAT compared to inpatient treatment.
Methods
The Cochrane Library, MEDLINE, Embase, PubMed and Web of Science databases were searched for studies comparing the costs of parenteral antimicrobial treatment without restriction on study design and year. Two reviewers conducted eligibility screening and cross-validated the extracted data. The cost data were adjusted and inflated to 2023 US dollars. A random effect model calculated mean differences (MD) with 95% confidence intervals (CI). The review protocol was registered on PROSPERO (CRD42024584201).
Results
Twenty studies involving 2790 patients were included in the systematic review, and six studies (three randomized controlled trials and three cohorts) were subject to metanalysis. Collectively, these included 560 patients who received treatment in outpatient settings, and 491 treated as inpatients. The cost of parenteral antimicrobial per episode of care was lower in the outpatient settings MD −$5436.73 (95% CI: −$9589.24 to −$1284.22, I² = 96%; P = 0.01) than in inpatient settings.
Conclusions
OPAT significantly saves costs compared to inpatient treatment. We recommend comprehensive analysis of treatment costs from all perspectives, including various cost types.
Autor:innen und Institutionen
- UQ Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia.
- Department of Pharmacy, Wollo University, Dessie, Ethiopia.
- Department of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
- Herston Infectious Disease Institute (HeIDI), Metro North Health, Brisbane, QLD, Australia.
- Division of Anaesthesiology Critical Care Emerging and Pain Medicine, Nimes University Hospital, University of Montpellier, Nîmes, France.
- Hospital Universitario de Torrejón, Unidad de Hospitalización a Domicilio, Madrid, Spain.
ORCID-Profile: Luis Eduardo López Cortés, Kate McCarthy, Mark Gilchrist, Fekade B Sime
Zitieren
APA
Mohammed, S. A., Roberts, J. A., Mirón-Rubio, M., López Cortés, L. E., Assefa, G. M., Pollard, J., McCarthy, K., Gilchrist, M., Cotta, M., & Sime, F. B. (2025). Quantifying cost savings from outpatient parenteral antimicrobial therapy programme: a systematic review and meta-analysis. JAC-Antimicrobial Resistance, 7(2). https://doi.org/10.1093/jacamr/dlaf049
Vancouver
Mohammed SA, Roberts JA, Mirón-Rubio M, López Cortés LE, Assefa GM, Pollard J, et al. Quantifying cost savings from outpatient parenteral antimicrobial therapy programme: a systematic review and meta-analysis. JAC-Antimicrobial Resistance. 2025;7(2). doi:10.1093/jacamr/dlaf049
BibTeX
@article{Mohammed2025,
author = {Mohammed, Solomon Ahmed and Roberts, Jason A and Mirón-Rubio, Manuel and López Cortés, Luis Eduardo and Assefa, Getnet Mengistu and Pollard, James and McCarthy, Kate and Gilchrist, Mark and Cotta, Menino and Sime, Fekade B},
title = {Quantifying cost savings from outpatient parenteral antimicrobial therapy programme: a systematic review and meta-analysis},
journal = {JAC-Antimicrobial Resistance},
year = {2025},
volume = {7},
number = {2},
doi = {10.1093/jacamr/dlaf049}
}
EUVIMED